Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="greed, post: 5510806"]<font size="6"><b>Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains</b></font></p><p>September 11, 2015 | By <a href="http://www.fiercepharma.com/author/chelfand" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://www.fiercepharma.com/author/chelfand" rel="nofollow">Carly Helfand</a></p><p><a href="http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11#disqus_thread" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11#disqus_thread" rel="nofollow"></a></p><p>Typically, the first generics for blockbuster meds get off to a running start. Not so with Novartis' generic of Teva's multiple sclerosis standout <a href="http://www.fiercepharma.com/tags/copaxone" target="_blank" class="externalLink ProxyLink" data-proxy-href="http://www.fiercepharma.com/tags/copaxone" rel="nofollow">Copaxone</a>, though--and Bernstein analyst Ronny Gal thinks he can explain why.</p><p><br /></p><p>The Swiss pharma giant's knockoff, dubbed Glatopa, right now has market share of only about 20%--as opposed to the roughly 50% some industry-watchers say it's capable of snagging. And that could be because coverage of the copy is "considerably behind that of Copaxone," he wrote in a Friday note to clients.</p><p><br /></p><p>Copaxone reaches the "best available coverage" tier for 59% of covered lives, he pointed out, while Glatopa can only boast that level for 31%. Many payers have kept Teva's original as either preferred or equally accessible thanks to discounting, he noted, and on top of that, Glatopa--likely thanks to its high price--is treated by many plans as a branded product.</p><p><br /></p><p>"It appears that the lower penetration is, for the most part, factual and simply reflects current formulary status coverage," Gal wrote. Teva is offering more discount to payers, and those payers are preferring its brand over equally or slightly more expensive Glatopa."</p><p><br /></p><p>Novartis' Sandoz unit, though, appears to be taking that tack deliberately. It "can always lower its price and capture share," Gal noted, but right now, it "appears to be interested in building share cautiously in order to protect market price."[/QUOTE]</p><p><br /></p>
[QUOTE="greed, post: 5510806"][SIZE=6][B]Why is Novartis' Copaxone copy lagging? It's all about coverage, analyst explains[/B][/SIZE] September 11, 2015 | By [URL='http://www.fiercepharma.com/author/chelfand']Carly Helfand[/URL] [URL='http://www.fiercepharma.com/story/why-novartis-copaxone-copy-lagging-its-all-about-coverage-analyst-explains/2015-09-11#disqus_thread'][/URL] Typically, the first generics for blockbuster meds get off to a running start. Not so with Novartis' generic of Teva's multiple sclerosis standout [URL='http://www.fiercepharma.com/tags/copaxone']Copaxone[/URL], though--and Bernstein analyst Ronny Gal thinks he can explain why. The Swiss pharma giant's knockoff, dubbed Glatopa, right now has market share of only about 20%--as opposed to the roughly 50% some industry-watchers say it's capable of snagging. And that could be because coverage of the copy is "considerably behind that of Copaxone," he wrote in a Friday note to clients. Copaxone reaches the "best available coverage" tier for 59% of covered lives, he pointed out, while Glatopa can only boast that level for 31%. Many payers have kept Teva's original as either preferred or equally accessible thanks to discounting, he noted, and on top of that, Glatopa--likely thanks to its high price--is treated by many plans as a branded product. "It appears that the lower penetration is, for the most part, factual and simply reflects current formulary status coverage," Gal wrote. Teva is offering more discount to payers, and those payers are preferring its brand over equally or slightly more expensive Glatopa." Novartis' Sandoz unit, though, appears to be taking that tack deliberately. It "can always lower its price and capture share," Gal noted, but right now, it "appears to be interested in building share cautiously in order to protect market price."[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Pharma/Biotech Companies
>
Novartis
>
Novartis milestones be proud ! Management take a bow !
>